Aligos Therapeutics (ALGS) Accumulated Expenses (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Accumulated Expenses came in at $4.2 million in Q1 2026, up 22.33% YoY from $3.4 million in Q1 2025, and down 68.81% on a QoQ basis from $13.5 million in Q4 2025.
Aligos Therapeutics (ALGS) Accumulated Expenses (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Accumulated Expenses data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Accumulated Expenses rose 22.33% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (up 22.33% YoY) and the FY2025 annual result came in at $13.5 million, up 111.77% from the prior year.
- Accumulated Expenses fell to $4.2 million in Q1 2026, from $13.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $13.8 million in Q2 2023 to a low of $3.1 million in Q1 2023.
- A 5-year average of $8.0 million and a median of $6.4 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses sank 83.21% — and 2023, when it jumped 331.09%.
- Tracing ALGS's Accumulated Expenses over 5 years: stood at $6.3 million in 2022, then rose by 5.97% to $6.7 million in 2023, then retreated by 4.29% to $6.4 million in 2024, then soared by 111.77% to $13.5 million in 2025, then sank by 68.81% to $4.2 million in 2026.
- The last three Accumulated Expenses figures came in at $4.2 million (Q1 2026), $13.5 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.70 Mn |
| Mar 31, 2026 | 4.22 Mn |
| Dec 31, 2025 | 13.53 Mn |
| Sep 30, 2025 | 13.61 Mn |
| Jun 30, 2025 | 12.21 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Dec 31, 2024 | 6.39 Mn |
| Sep 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 12.06 Mn |
| Mar 31, 2024 | 12.04 Mn |
| Dec 31, 2023 | 6.67 Mn |
| Sep 30, 2023 | 4.08 Mn |
| Jun 30, 2023 | 13.80 Mn |
| Mar 31, 2023 | 3.09 Mn |
| Dec 31, 2022 | 6.30 Mn |
| Sep 30, 2022 | 13.68 Mn |
| Jun 30, 2022 | 3.20 Mn |
| Mar 31, 2022 | 3.54 Mn |
| Dec 31, 2021 | 25.39 Mn |
| Sep 30, 2021 | 22.76 Mn |